clinical trial · NCT05944562

Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome

Washington University School of Medicine →·phase1·active not recruiting·n = 24

Mycosis FungoidesSezary SyndromeMycosis Fungoides/Sezary SyndromeTulmimetostat

brief summary

The hypotheses of this study are that single agent DZR123 will be safe and well tolerated in patients with advanced (stage IB-IVB) mycosis fungoides (MF)/Sézary syndrome (SS) who have had at least one prior systemic therapy, and that in these patients, DZR123 will demonstrate efficacy and be worth of further study.

started

Jan 9, 2024

primary completion

Feb 28, 2027

completion

Jan 31, 2029

last updated

Feb 11, 2026

official title

Phase I Study With an Expansion Cohort of Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol